Boehringer Ingelheim Unit Looks to Sell Generics Business

Ben Venue Laboratories has hired Bank of America Merrill Lynch to explore a possible sale of its generic sterile injectable drugs business.
Dec. 5, 2013

Ben Venue Laboratories, the Bedford, Ohio-based subsidiary of German drugmaker Boehringer Ingelheim, has hired Bank of America Merrill Lynch to explore a possible sale of its generic sterile injectable drugs business.

Ben Venue had struggled to keep the Ohio site open after a series of drug quality problems and had been operating under a consent decree with FDA until ultimately deciding in October to cease production and avoid additional investment.

No potential sale price or bidders have been mentioned yet.

Read the Reuters release

Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates